Duality Advisers’s Pacira BioSciences PCRX Stock Holding History

Duality Advisers’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-34,784	Closed	-$1.02M	–	392
2024 Q1	$1.02M	Buy	34,784 +605	+2%	+$18.6K	0.1%	321
2023 Q4	$1.15M	Buy	34,179 +1,591	+5%	+$46.5K	0.12%	282
2023 Q3	$1,000K	Buy	32,588 +5,241	+19%	+$189K	0.12%	289
2023 Q2	$1.1M	Buy	+27,347	New	+$1.13M	0.14%	266
2023 Q1	–	Sell	-14,164	Closed	-$547K	–	713
2022 Q4	$547K	Buy	+14,164	New	+$689K	0.06%	422
2021 Q4	–	Sell	-10,000	Closed	-$560K	–	644
2021 Q3	$560K	Sell	10,000 -13,326	-57%	-$768K	0.04%	433
2021 Q2	$1.42M	Buy	+23,326	New	+$1.48M	0.13%	277
2021 Q1	–	Sell	-25,251	Closed	-$1.51M	–	662
2020 Q4	$1.51M	Buy	+25,251	New	+$1.48M	0.11%	272

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Duality Advisers's PCRX Position: Q2 2024 in Review

Duality Advisers sold out of Pacira BioSciences (PCRX) in Q2 2024, closing a stake of 34,784 shares — an estimated $1.02M sold.

Duality Advisers first reported a position in PCRX in Q4 2020 and held it in 8 quarters. The position peaked at $1.51M in Q4 2020. 280 funds tracked by Wall St. Rank hold PCRX as of Q2 2024.

Duality Advisers reported no remaining Pacira BioSciences position as of Q2 2024 after selling out during the quarter.
Duality Advisers sold 34,784 Pacira BioSciences shares in Q2 2024, an estimated $1.02M.
Duality Advisers first reported a position in Pacira BioSciences in Q4 2020 and held it in 8 quarters.
Duality Advisers's Pacira BioSciences position peaked at $1.51M in Q4 2020.
280 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.